Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Vigabatrin
Dowelhurst Ltd
N03AG04
Vigabatrin
500mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04080100
1. WHAT SABRIL IS AND WHAT IT IS USED FOR 2. BEFORE YOU TAKE SABRIL 3. HOW TO TAKE SABRIL PACKAGE LEAFLET: INFORMATION FOR THE USER SABRIL ® 500MG TABLETS (vigabatrin) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Sabril 500mg tablets but it will be referred to as Sabril throughout this leaflet. WHAT IS IN THIS LEAFLET: 1. What Sabril is and what it is used for 2. What you need to know before you take Sabril 3. How to take Sabril 4. Possible side effects 5. How to store Sabril 6. Contents of the pack and other information Sabril is used to help control various forms of epilepsy. It is used together with your current medication to treat ‘difficult to control’ epilepsy. It will initially be prescribed by a specialist. Your response to the treatment will be monitored. It is also used to control infantile spasms (West’s syndrome). DO NOT TAKE SABRIL x if you are allergic to vigabatrin or any of the other ingredients of this medicine (listed in Section 6). WARNINGS AND PRECAUTIONS Talk to your doctor before taking Sabril if: ▲ you are breast-feeding ▲ you are pregnant or plan to become pregnant ▲ you have or have had depression or any other psychiatric illness in the past ▲ you have had any kidney problems ▲ you have had any problems with your eyes If you develop symptoms like sleepiness, reduced consciousness and movements (stupor) or confusion consult your doctor who will decide upon a dose reduction or withdrawal. A small number of people being treated with antiepileptics s Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sabril 500 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 500mg vigabatrin For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet White to off-white, oval, biconvex, tablets with a break-line on one side and “Sabril” engraved on the other side. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. Monotherapy in the treatment of infantile spasms (West’s syndrome). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Sabril treatment may only be initiated by a specialist in epileptology, neurology or paediatric neurology. Follow-up should be arranged under supervision of a specialist in epileptology, neurology or paediatric neurology. Posology Sabril is for oral administration once or twice daily and may be taken before or after meals. If the control of epilepsy is not clinically significantly improved after an adequate trial, vigabatrin treatment should not be continued. Vigabatrin should be gradually withdrawn under close medical supervision. Adults Maximal efficacy is usually seen in the 2- 3g/day range. A starting dose of 1g daily should be added to the patient’s current antiepileptic medicinal product regimen. The daily dose should then be titrated in 0.5g increments at weekly intervals depending on clinical response and tolerability. The highest recommended dose is 3g/day. No direct correlation exists between the plasma concentration and the efficacy. The duration of the effect of the medicinal product is dependent on the rate of GABA transaminase resynthesis rather than the concentration of the drug i Read the complete document